Bio Tech
Trius Therapeutics, Inc. (TSRX)
Triusrx.com
Phone: 858.452.0370
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. They have successfully completed their first Phase 3 clinical trial for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.
Zacks Small Cap Research Report
InVivo Therapeutics Corp (NVIV.OB)
http://www.invivotherapeutics.com
Phone: 617-475-1520
InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI). Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology.
Zacks Small Cap Research Report
IMMUNOCELLULAR THERA (IMUC.OB)
http://www.imuc.com
Phone: (818) 992-2907
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer. Their products and technologies are designed to harness the power of the immune system to improve the treatment and diagnosis of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence.
Zacks Small Cap Research Report
AEterna Zentaris, Inc. (NASDAQ: AEZS)
http://www.aezsinc.com
Phone: 418-652-8525
Aeterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Companyís pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and colorectal cancer, combined with its Phase I program in multiple cancers, as well as the further advancement of AEZS-108
Bion Environmental Technologies Inc. (OTCQB: BNET)
http://www.biontech.com
Phone: 212-758-6622
Bion Environmental Technologies, Inc. provides an environmental solution to a significant source of pollution in the United States agriculture, Confined Animal Feeding Operations (CAFO’s). The Company is pursuing business opportunities in two areas: retrofit and environmental remediation of existing CAFOs to reduce nutrient (nitrogen and phosphorus) releases and gaseous emissions (ammonia, greenhouse gases and volatile organic compounds in order to clean the air and water in the surrounding areas.
Recent Comments